全文获取类型
收费全文 | 2437篇 |
免费 | 134篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 126篇 |
妇产科学 | 127篇 |
基础医学 | 247篇 |
口腔科学 | 54篇 |
临床医学 | 271篇 |
内科学 | 548篇 |
皮肤病学 | 48篇 |
神经病学 | 82篇 |
特种医学 | 180篇 |
外科学 | 243篇 |
综合类 | 136篇 |
预防医学 | 177篇 |
眼科学 | 20篇 |
药学 | 181篇 |
1篇 | |
中国医学 | 74篇 |
肿瘤学 | 55篇 |
出版年
2021年 | 22篇 |
2020年 | 17篇 |
2018年 | 19篇 |
2017年 | 25篇 |
2016年 | 25篇 |
2015年 | 45篇 |
2014年 | 52篇 |
2013年 | 74篇 |
2012年 | 96篇 |
2011年 | 93篇 |
2010年 | 77篇 |
2009年 | 60篇 |
2008年 | 88篇 |
2007年 | 72篇 |
2006年 | 75篇 |
2005年 | 58篇 |
2004年 | 52篇 |
2003年 | 58篇 |
2002年 | 54篇 |
2001年 | 58篇 |
2000年 | 53篇 |
1999年 | 48篇 |
1998年 | 58篇 |
1997年 | 65篇 |
1996年 | 60篇 |
1995年 | 50篇 |
1994年 | 63篇 |
1993年 | 47篇 |
1992年 | 53篇 |
1991年 | 43篇 |
1990年 | 34篇 |
1989年 | 43篇 |
1988年 | 34篇 |
1987年 | 42篇 |
1986年 | 30篇 |
1985年 | 26篇 |
1984年 | 27篇 |
1983年 | 22篇 |
1982年 | 23篇 |
1981年 | 29篇 |
1980年 | 21篇 |
1978年 | 15篇 |
1976年 | 16篇 |
1959年 | 35篇 |
1958年 | 58篇 |
1957年 | 87篇 |
1956年 | 45篇 |
1955年 | 75篇 |
1954年 | 67篇 |
1953年 | 17篇 |
排序方式: 共有2584条查询结果,搜索用时 15 毫秒
1.
2.
宫腹腔镜联合手术诊治不孕症150例分析 总被引:14,自引:0,他引:14
目的:探讨宫腹腔镜联合手术在诊治不孕症中的应用。方法:对150例不孕症患者行宫腹腔镜联合手术,对不孕症病因进行诊断,同时行治疗。结果:盆腔粘连和输卵管阻塞是不孕症的主要原因。子宫内膜息肉和正常盆腔占次要比例。子宫内膜异位症和多囊卵巢也是主要病因。150例同时行宫腹腔镜输卵管通液和各种疾病的治疗。联合手术后妊娠率为48.8%。结论:腹腔镜联合手术,在一次麻醉下,可以对不孕的原因全面评价和明确诊断,在诊断同时进行治疗,对不孕症的诊断和治疗有重大的意义,值得推广。 相似文献
3.
Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study 总被引:1,自引:0,他引:1
M. J. V?lim?ki K. Laitinen K. Laitinen A. Patronen H. Puolijoki H. Puolijoki J. Sepp?nen L. Pylkk?nenand the Probone Study Group 《Osteoporosis international》2002,13(12):937-947
This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the
prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53
years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was
at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800
mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days
for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of
2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg
of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening,
and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were
−3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to
4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference
between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5%
in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between
groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral
neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between
clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate
in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually
within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose
of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively
reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective,
placebo-controlled trials.
Received: 4 March 2002 / Accepted: 9 July 2002 相似文献
4.
5.
6.
Tc-99m HMPAO labeled leukocytes superior to bone scan in the detection of osteomyelitis in children.
Seven children (aged 7 to 16 years) with confirmed osteomyelitis underwent imaging with Tc-99m HMPAO labeled leukocytes and with Tc-99m diphosphonates. The patients were scanned at 1/2 hour and at 3 hours. The scans were evaluated visually, and the lesion-to-normal bone ratios were quantitated. All the lesions on leukocyte scans and six out of seven lesions in bone scans were readily detectable 1/2 hour after injection of the radiopharmaceutical, but 3 hours is the better imaging time. In quantitative analysis, the lesion-to-normal bone ratio increased with leukocytes significantly higher than with the bone scans (P less than 0.05). When the scintigraphic findings were compared with surgical and radiologic results, the leukocyte images detected and localized lesions better than the bone scans. According to these preliminary results, Tc-99m HMPAO labeled leukocytes seem to offer a rapid and accurate method for detecting bone infections. 相似文献
7.
Acute respiratory distress during Caesarean section under spinal anaesthesia A probable case of anaphylactoid reaction to Syntocinon 总被引:2,自引:0,他引:2
A case of life-threatening respiratory distress during a Caesarean section under spinal anaesthesia is reported. Possible causes of the event including anaphylactoid reactions and the methods of their diagnosis are discussed. The most likely cause of the episode was felt to be an anaphylactoid reaction to Syntocinon. 相似文献
8.
Abstract: This paper dicusses the use of esophageal dilatation with a Rigiflex TTS balloon. This method was used 45 times on 11 patients affected by anastomotic or a severe grade peptic esophageal stenosis. Fluoroscopic guidance was used in 36 procedures (80%) without effecting the mean duration of the treatment (12 minutes). The results were considered satisfactory when these goals had been achieved: a) dilatation of the stenosis over 15 mm; b) a dysphagia free-time of more than 6 months. A satisfactory result was achieved in 10 patients (90.9%), without deaths and major complications. 5 patients received 1 dilatation and the other 5 needed, 3-3-4-7–11 procedures respectively to obtain a satisfactory result. On these basis we consider that its great efficacy, security and tolerability depend on the following characteristics of the Rigiflex TTS balloon: 1) “radial” dilatation; 2) the possibility of introducing the balloon through the operative channel of the fiberscope; 3) direct visualization of the stenosis during dilatation. The following disadvantages with this method are: the absence of a tactile sensation of dilatation and the elevated cost of the instrument. We conclude that the Rigiflex TTS balloon is an important alternative to guide-wire techniques, especially for the treatment of severe esophageal strictures. 相似文献
9.
妊娠肝内胆汁淤积症患者血清一氧化氮和内皮素的变化及意义 总被引:2,自引:0,他引:2
目的:探讨妊娠肝内胆汁淤积症(ICP)患者外周静脉血清、新生儿脐静脉血清中一氧化氮(NO)、内皮素(ET)、丙二醛(MDA)和超氧化物歧化酶(SOD)含量的变化及在ICP发病中的作用。方法:以ICP组28例为研究组,测定其外周静脉血清及新生儿脐静脉血清中的NO、ET、MDA和SOD,以年龄相近的24例正常孕妇作为对照组。结果:ICP患者的MDA和ET含量较正常晚期妊娠显著增高(P<0.01),ICP患者的NO和SOD含量与对照组相比无显著性差异(P>0.05)。母血清中NO、ET、MDA含量均较新生儿脐静脉血清中的含量高,差异有显著性(P<0.01)。结论:妊娠期体内氧化和抗氧化失衡及ET水平的增高可能与ICP的发生、发展有关。 相似文献
10.
Kalevi Laitinen David Sinclair Maria Nurmi Reija Hietala Heikki Kröger Kalervo Kiianmaa Mikko Salaspuro 《Alcoholism, clinical and experimental research》1992,16(5):875-880
Previous work has shown that calcitonin inhibits eating by rats and that it affects several neurotransmitter systems suspected to play a role in alcohol consumption. The present study was an initial test of whether calcitonin does affect voluntary alcohol consumption by male Wistar rats with prolonged alcohol experience. Calcitonin (20 IU/kg) or saline was injected subcutaneously on 10 consecutive days when the rats (n = 20) had continual access to 10% (v/v) ethanol solution, and to food and water. Using a cross-over design, the effects of 40 IU/kg calcitonin vs. saline were then examined in a second 10-day treatment period. Similar patterns of effects were obtained with both calcitonin doses, but the patterns differed with alcohol, food, and water intake. Alcohol drinking showed biphasic changes with both doses, producing highly significant Treatment x Day interactions (p < 1E-10 and p = 6E-7): it was significantly reduced on the first day of calcitonin treatment and significantly increased on the last few days. Food intake was reduced on all calcitonin days although most markedly on the first. Water drinking was not altered on the first calcitonin day, but was greatly increased on the second, then gradually returned toward the baseline. In a second experiment, the animals were switched to 1 hr of alcohol access per day, and calcitonin (20 IU/kg) was administered periodically to one group 4 hr before the alcohol access. Alcohol drinking was significantly reduced in all cases when the calcitonin injection was preceded by at least 1 day without calcitonin.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献